JP2006516633A - Ｈｉｖ−１及びｈｉｖ−２を処置するための治療用組成物 - Google Patents

Ｈｉｖ−１及びｈｉｖ−２を処置するための治療用組成物 Download PDF

Info

Publication number
JP2006516633A
JP2006516633A JP2006503151A JP2006503151A JP2006516633A JP 2006516633 A JP2006516633 A JP 2006516633A JP 2006503151 A JP2006503151 A JP 2006503151A JP 2006503151 A JP2006503151 A JP 2006503151A JP 2006516633 A JP2006516633 A JP 2006516633A
Authority
JP
Japan
Prior art keywords
amount
present
nimodipine
inulin
desferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503151A
Other languages
English (en)
Japanese (ja)
Inventor
ボグスロウ，ジェレン
Original Assignee
エクシトン−エクシマー ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/353,483 external-priority patent/US20030203045A1/en
Application filed by エクシトン−エクシマー ゲーエムベーハー filed Critical エクシトン−エクシマー ゲーエムベーハー
Publication of JP2006516633A publication Critical patent/JP2006516633A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006503151A 2003-01-29 2004-01-29 Ｈｉｖ−１及びｈｉｖ−２を処置するための治療用組成物 Pending JP2006516633A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/353,483 US20030203045A1 (en) 2002-04-30 2003-01-29 Therapeutic composition for the treatment of HIV-1 and HIV-2
PCT/US2004/002536 WO2004066954A2 (fr) 2003-01-29 2004-01-29 Composition therapeutique destinee au traitement du virus hiv-1 et hiv-2

Publications (1)

Publication Number Publication Date
JP2006516633A true JP2006516633A (ja) 2006-07-06

Family

ID=32823743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503151A Pending JP2006516633A (ja) 2003-01-29 2004-01-29 Ｈｉｖ−１及びｈｉｖ−２を処置するための治療用組成物

Country Status (9)

Country Link
EP (1) EP1589961A4 (fr)
JP (1) JP2006516633A (fr)
KR (1) KR20050094461A (fr)
CN (1) CN1747726A (fr)
AU (1) AU2004206996A1 (fr)
CA (1) CA2514252A1 (fr)
RU (1) RU2005123957A (fr)
WO (1) WO2004066954A2 (fr)
ZA (1) ZA200505977B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021161045A (ja) * 2020-03-31 2021-10-11 株式会社古川リサーチオフィス 亜鉛化合物配合組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101810625B (zh) * 2010-04-09 2012-05-23 上海新康制药厂 蒲公英甾醇的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
CA1337047C (fr) * 1988-08-18 1995-09-19 Peter Dodd Cooper Compositions a base de gamma inuline
JP3479532B2 (ja) * 1989-03-31 2003-12-15 ザ・チルドレンズ・メディカル・センター・コーポレーション エイズの痴呆症、脊髄障害および失明の治療
US5977073A (en) * 1991-06-06 1999-11-02 Life Sciences' Technologies, Inc. Nutrient composition for treatment of immune disorders
RU2107502C1 (ru) * 1997-03-27 1998-03-27 Открытое акционерное общество "Ветеринарные препараты" Ветеринарный препарат, обладающий широким спектром действия, - йод однохлористый
AU4944500A (en) * 1999-06-29 2001-01-31 Robert H. Jacobs A method for optimizing immune activity in the treatment of auto-immune diseases and chronic immune conditions
RU2195277C2 (ru) * 2001-02-09 2002-12-27 Третьяков Василий Васильевич Способ лечения вич-инфекций
GB2374008B (en) * 2001-04-04 2005-03-16 John Carter Pharmaceutical compositions comprising copper and zinc
PL353693A1 (en) * 2002-04-30 2003-11-03 Bogusław Jeleń Compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd4+ cells of human immunological system at all stages of infection and in the aids syndrome as well as method of manufacture of compound pharmaceutical for inhibiting replication of hiv-1 and hiv-2 viruses in the cd+ cells of human immunological system at all stages of infection and in the aids syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021161045A (ja) * 2020-03-31 2021-10-11 株式会社古川リサーチオフィス 亜鉛化合物配合組成物

Also Published As

Publication number Publication date
RU2005123957A (ru) 2006-01-27
WO2004066954A3 (fr) 2005-03-17
AU2004206996A1 (en) 2004-08-12
KR20050094461A (ko) 2005-09-27
CA2514252A1 (fr) 2004-08-12
CN1747726A (zh) 2006-03-15
ZA200505977B (en) 2006-05-31
EP1589961A2 (fr) 2005-11-02
WO2004066954A2 (fr) 2004-08-12
EP1589961A4 (fr) 2006-02-15

Similar Documents

Publication Publication Date Title
JP2007513190A5 (fr)
TW200914011A (en) Therapeutic compositions and methods
JPH08509736A (ja) 光学的に純粋な（−）パントプラゾールを用いる胃の疾患治療の方法と組成
JP2012502103A5 (fr)
JP2021152002A5 (fr)
WO2007078848A3 (fr) Préparation de sels pharmaceutiques de l'acide 3-o-(3',3'-diméthylsuccinyl)bétulinique
JP2006516633A (ja) Ｈｉｖ−１及びｈｉｖ−２を処置するための治療用組成物
JPH08509738A (ja) 光学的に純粋な（＋）パントプラゾールを用いる胃の疾患治療の方法と組成
JPH0136445B2 (fr)
Hassan-Alin et al. Studies on drug interactions between esomeprazole, amoxicillin and clarithromycin in healthy subjects.
US20030203045A1 (en) Therapeutic composition for the treatment of HIV-1 and HIV-2
WO2020238932A1 (fr) Utilisation d'un inhibiteur de parp en combinaison avec un inhibiteur de vegfr pour traiter le cancer de l'ovaire ou le cancer du sein
CA2505106A1 (fr) Composition de valdecoxibe liquide concentre
Witvrouw et al. Potent and selective inhibition of HIV and SIV by prostratin interacting with viral entry
KR100900915B1 (ko) 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법
JP2012067129A (ja) 点眼剤
JP5977672B2 (ja) イブプロフェンリシナートの経口投与用の懸濁液
US9446060B2 (en) Method of producing therapeutic agent
JP4961671B2 (ja) 点眼剤
KR20160009677A (ko) 암 치료를 위한 ro5503781, 카페시타빈과 옥살리플라틴의 조합
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
WO2018042332A1 (fr) Combinaisons, utilisations et traitements correspondants
JPH06502846A (ja) Ｃｄ４及び抗ｈｉｖポリアニオン剤からなる薬剤組成体及びその利用方法
Tobin Recent progress in anti-HIV broadly neutralizing antibody research
AU629520B2 (en) A medicament